Here's Why You Should Retain Penumbra Stock in Your Portfolio Now

Penumbra, Inc. (PEN) is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company's robust portfolio expansion looks promising. However, the impact of forex woes is a headwind. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) company has lost 16.2% against the industry's 17.8% growth and the S&P 500's 30.4% rise. The global healthcare provider company has a market capitalization of $8.67 billion. PEN beat on ...